IP Library › Granted Patent US 12,214,026
Granted Patent B2
US 12,214,026 · App. 18/154,642 · Granted Feb 4, 2025

Vaccine for falciparum malaria

Inventors: Jonathan Kurtis (Providence, RI); Christian Parcher Nixon (Little Compton, RI); Dipak Kumar Raj (Pawtucket, RI); Jennifer Frances Friedman (Providence, RI); Michal Fried (Rockville, MD); Patrick Emmet Duffy (Washington, DC)
Assignees: RHODE ISLAND HOSPITAL; SEATTLE CHILDREN'S HOSPITAL
A61K39/015A61K39/39575C07K14/445C07K16/205C07K16/44A61K2039/505A61K2039/522A61K2039/54A61K2039/55A61K2039/575C07K2317/34C07K2317/76Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,026
App. No.
18/154,642
Granted
Feb 4, 2025
Kind
B2
Abstract

The invention provides compositions and methods for preventing or reducing the severity of malaria.

Claims (12)

1. A method for reducing the severity of malaria or immunizing against malaria in a subject, comprising the step of administering a composition to the subject;

wherein the composition comprises a polypeptide selected from the group consisting of: CDPK5 (SEQ ID NO: 47), SERA5 (SEQ ID NOS: 70, 72), PfSUB1 (SEQ ID NO: 74), and PfPKG (SEQ ID NO: 76) or a combination of polypeptides thereof;

wherein the administration of the composition including the polypeptide or combination of polypeptides elicits an immune response to the polypeptide or combination of polypeptides;

wherein the immune response inhibits schizont egress from red blood cells;

thereby reducing the severity of malaria or immunizing against malaria in the subject.

2. The method of claim 1 , wherein the immune response is an antibody response.

3. The method of claim 1 , wherein the immune response is a cellular immune response.

4. The method of claim 1 , wherein the composition comprises the polypeptide PfSERA5.

5. The method of claim 1 , wherein the composition further comprises the polypeptide PfSEP- 1 A.

6. The method of claim 1 , wherein the subject is a human.

7. The method of claim 1 , wherein the subject is an adolescent female or a female of childbearing age.

8. The method of claim 1 , wherein the composition is administered intramuscularly.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: SEATTLE BIOMEDICAL RESEARCH INSTITUTE
To: SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
Reel/Frame 067725/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: FRIED, MICHAL; DUFFY, PATRICK EMMET
To: SEATTLE BIOMEDICAL RESEARCH INSTITUTE
Reel/Frame 067651/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: KURTIS, JONATHAN; NIXON, CHRISTIAN PARCHER; RAJ, DIPAK KUMAR; FRIEDMAN, JENNIFER FRANCES
To: RHODE ISLAND HOSPITAL
Reel/Frame 067635/0363 →
Continuity (7)
Division 17178111 · Feb 17, 2021
Continuation 16283472 · Feb 22, 2019
Division 15607203 · May 26, 2017
Continuation 14361573
Provisional Application 61641445 · May 2, 2012
Provisional Application 61566365 · Dec 2, 2011
Related Publication 20230293654A1 · Sep 21, 2023
References Cited (113)
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4501728A · Geho et al. · 1985 [cited by applicant]
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 4837028A · Allen · 1989 [cited by applicant]
US 4873316A · Meade et al. · 1989 [cited by applicant]
US 5019369A · Presant et al. · 1991 [cited by applicant]
US 5204253A · Sanford et al. · 1993 [cited by applicant]
US 5279833A · Rose · 1994 [cited by applicant]
US 5580859A · Felgner et al. · 1996 [cited by applicant]
US 5589466A · Felgner et al. · 1996 [cited by applicant]
US 5700671A · Prieto et al. · 1997 [cited by applicant]
US 5750176A · Prieto et al. · 1998 [cited by applicant]
US 5849589A · Tedder et al. · 1998 [cited by applicant]
US 9662379B2 · Kurtis et al. · 2017 [cited by applicant]
US 10213502B2 · Kurtis et al. · 2019 [cited by applicant]
US 10272145B2 · Kurtis et al. · 2019 [cited by applicant]
US 20040137512A1 · Horii · 2004 [cited by applicant]
US 20050136067A1 · Klein et al. · 2005 [cited by applicant]
US 20100310602A1 · Reed et al. · 2010 [cited by applicant]
US 20140341918A1 · Kurtis et al. · 2014 [cited by applicant]
US 20170258884A1 · Kurtis et al. · 2017 [cited by applicant]
US 20170326219A1 · Kurtis et al. · 2017 [cited by applicant]
US 20200023047A1 · Kurtis et al. · 2020 [cited by applicant]
EP 0264166A1 · 1988 [cited by applicant]
WO 8606075A1 · 1986 [cited by applicant]
WO 9106309A1 · 1991 [cited by applicant]
WO 9324640A2 · 1993 [cited by applicant]
WO 9618372A2 · 1996 [cited by applicant]
WO 2007140506A1 · 2007 [cited by applicant]
WO 2013082500A2 · 2013 [cited by applicant]
“Human Vaccines & Immunotherapeutics: News”, Human Vaccines and Immunotherapeutics, vol. 16, No. 6 https://doi.org/10.1080/21645515.2020.1778422, 2020, pp. 1226-1227. [cited by applicant]
“European Search Report received for European Patent Application No. 12854476.4, mailed on Jul. 6, 2016”, 11 pages. [cited by applicant]
“Extended European Search Report received for European Patent Application No. 21186416.0, mailed on Mar. 18, 2022”, 9 pages. [cited by applicant]
“Final Office Action received for U.S. Appl. No. 14/361,573, mailed on Mar. 18, 2016”, 18 pages. [cited by applicant]
“GenBank Accession No. XM_001347460”, May 27, 2010. [cited by applicant]
“GenBank Accession No. XM_001347496”, May 27, 2010. [cited by applicant]
“International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2012/067404, mailed on Jul. 10, 2013”, 15 pages. [cited by applicant]
“Non-Final Office Action received for U.S. Appl. No. 14/361,573, mailed on Jul. 9, 2015”, 12 pages. [cited by applicant]
“Non-Final Office Action received for U.S. Appl. No. 16/283,472, mailed on Jun. 30, 2020”, 8 pages. [cited by applicant]
“Notice of Allowance received for U.S. Appl. No. 14/361,573, mailed on Sep. 28, 2016”, 7 pages. [cited by applicant]
“Notice of Allowance received for U.S. Appl. No. 16/283,472, mailed on Nov. 18, 2020”, 8 pages. [cited by applicant]
“Restriction Requirement received for U.S. Appl. No. 14/361,573, mailed on Feb. 13, 2015”, 11 pages. [cited by applicant]
“Restriction Requirement received for U.S. Appl. No. 16/283,472, mailed on Oct. 30, 2019”, 6 pages. [cited by applicant]
“Supplemental Notice of Allowance received for U.S. Appl. No. 14/361,573, mailed on Jan. 23, 2017”, 5 pages. [cited by applicant]
Allison , et al., “The Mode of Action of Immunological Adjuvants”, Developments in Biological Standardization, vol. 92, 1998, pp. 3-11. [cited by applicant]
Altschul, SF , et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs”, Nucleic Acids Research, vol. 25, No. 17, including BLAST search for SEQ ID No. 2, Sep. 1, 1997, pp. 3389-3402. [cited by applicant]
Amann , et al., “Tightly Regulated Tac Promoter Vectors Useful for the Expression of Unfused and Fused Proteins in [cited by applicant]
Aoki , et al., “Serine Repeat Antigen (SERA5) is Predominantly Expressed; among the SERA Multigene Family of Plasmodium Falciparum and the Acquired; Antibody Titers Correlate with Serum Inhibition of the Parasite Growth… [cited by applicant]
Baldari , et al., “A Novel Leader Peptide which Allows Efficient Secretion of a Fragment of Human Interleukin 1 Beta in [cited by applicant]
Banerji , et al., ““A Lymphocyte-Specific Cellular Enhancer is Located Downstream if the Joining Region in Immunoglobulin Heavy Chain Genes””, Cell, vol. 33 No. 3, Jul. 1983, pp. 729-740. [cited by applicant]
Blackman, Michael J., “Malarial Proteases and Host Cell Egress: An ‘Emerging’ Cascade”, Cellular Microbiology, vol. 10, No. 10, DOI: 10.111/j.1462-5822.2008.01176.x, Oct. 1, 2008, pp. 1925-1934. [cited by applicant]
Brunsvig , et al., ““Telomerase Peptide Vaccination” A Phase I/II Study in Patients with Non-Small Cell Lung Cancer”, Cancer Immunology, Immunotherapy, vol. 55, No. 12, Dec. 2006, pp. 1553-1564. [cited by applicant]
Bustamante , et al., “Differential Ability of Specific Regions of Plasmodium Falciparum Sexual Stage Antigen, Pfs230, to induce malaria transmission-blocking immunity”, Parasite Immunol, 22(8), Aug. 2000, pp. 373-380. [cited by applicant]
Byrne , et al., “Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice”, Proceedings of the National Academy of Sciences, vol. 86, No. 14, Jul. 1, 1989, pp. 5473-5477. [cited by applicant]
Calame , et al., “Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci”, Advances in Immunology, vol. 43, 1988, pp. 235-275. [cited by applicant]
Camper , et al., “Postnatal Repression of the Alpha-Fetoprotein Gene is Enhancer Independent”, Genes Dev., 3(4), Apr. 1989, pp. 537-546. [cited by applicant]
Cebere , et al., “Phase I Clinical Trial Safety of DNA- and Modified Virus Ankara-Vectored Human Immunodeficiency Virus Type I (HIV-1_ Vaccines Administered Alone and in a Prime-Boost Regime to Healthy HIV-1-Uninfected … [cited by applicant]
Cowman , et al., “The Cellular and Molecular Basis for Malaria Parasite Invasion of the Human Red Blood Cell”, J. Cell Biology, 198(6), Sep. 2012, pp. 961-971. [cited by applicant]
Dorvin , “Science”, Genbank Accession No. AOA5K1 K8HO, vol. 328, 2010, pp. 910-912. [cited by applicant]
Duffy , et al., “Malaria Vaccines Since 2000: Progress, Priorities, Products”, npj Vaccines, vol. 5, No. 48 https://doi.org/10.1038/s41541-020-0196.3, 2020, pp. 1-9. [cited by applicant]
Dupuis , et al., “Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection”, Cellular Immunology, vol. 186, No. 1, 1998, pp. 18-27. [cited by applicant]
Dvorin , et al., “A Plant-Like Kinase in Plasmodium Falciparum Regulates Parasite Egress from Erythrocytes”, Science, 328(910), May 14, 2020, 15 pages. [cited by applicant]
Edlund , et al., “Cell-Specific Expression of the Rat Insulin Gene: Evidence for Role of Two Distinct 5′ Flanking Elements”, Science, vol. 230. No. 4728, Nov. 22, 1985, pp. 912-916. [cited by applicant]
Felgner , et al., “Lipofection: A Highly Efficient, Lipid-Meditated DNA-Transfection Procedure”, Proceedings of the National Academy of Sciences, vol. 84, Nov. 1987, pp. 7413-7417. [cited by applicant]
Gabrilovich , et al., “IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of Cancer”, Journal of Immunotherapy with Emphasis on Tumor Immunology, vol. 19. No. 6, Nov. 1996, pp. 414-418. [cited by applicant]
Gardner, MJ , et al., “Genome Sequence of the Human Malaria Parasite Plasmodium Falciparum”, Nature, vol. 419, No. 6906 DOI: 10.1038/NATURE01097, Oct. 3, 2002, pp. 498-511. [cited by applicant]
Gottesman , et al., “Gene Expression Technology”, Methods in Enzymology, Academic Press, vol. 185, 1990, pp. 119-128. [cited by applicant]
Greenland , et al., “Problems Due to Small Samples and Sparse Data in Conditional Logistic Regression Analysis”, American Journal of Epidemiology, vol. 151, No. 5, Mar. 1, 2000, pp. 531-539. [cited by applicant]
Hall , et al., “Sequence of Plasmodium Falciparum Chromosomes 1, 3-9 and 13”, Nature 419, DOI: https://doi.org/10.1038/nature01095, Oct. 3, 2002, pp. 527-531. [cited by applicant]
Hon , et al., “Malaria According to GARP: A New Trait Towards Anti-Disease Vaccination”, Cell Press Reviews, Trends in Parasitology, vol. 36, No. 8, 2020, pp. 653-655. [cited by applicant]
Horii , et al., “Evidences of Protection Against Blood-Stage Infection of Plasmodium Falciparum by the Novel Protein Vaccine SE36”, Parasitol Int., 59(3), Sep. 2010, pp. 380-386. [cited by applicant]
Hurd, H , “A Promising New Malaria Vaccine Candidtae”, Bugbitten, https://blogs.biomedcentral.com/bugbitten/author/hhurd, May 15, 2020, 6 pages. [cited by applicant]
Kabyemela , et al., “Decreased Susceptibility to Plasmodium Falciparum Infection in Pregnant Women with Iron Deficiency”, J. Infect. Dis., 198(2), Jul. 15, 2008, pp. 163-166. [cited by applicant]
Kaslow , et al., “ [cited by applicant]
Kaufman , et al., “Translational Efficiency of Polycistronic mRNAs and their Utilization to Express Heterologous Genes in Mammalian Cells”, The EMBO Journal, vol. 6, No. 1, Jan. 1987, pp. 187-195. [cited by applicant]
Kessel , et al., “Murine Developmental Control Genes”, Science, vol. 249, No. 4967, Jul. 27, 1990, pp. 374-379. [cited by applicant]
Kurjan , et al., “Structure of a Yeast Pheromone Gene (MFa): A Putative a-Factor Precursor Contains Four Tandem Copies of Ma-ture a-Factor”, Cell, vol. 30, No. 3, Oct. 1982, pp. 933-943. [cited by applicant]
Lee , et al., “Arresting Malaria Parasite Egress from Infected Red Blood Cells”, Nature Chemical Biology, vol. 4, No. 3, DOI: 10.1038/nchembio0308-161, Mar. 1, 2008, pp. 161-162. [cited by applicant]
Luckow , et al., “High Level Expression of Nonfused Foreign Genes with Autographa Californica Nuclear Polyhedrosis Virus Expression Vectors”, Virology, vol. 170, No. 1, May 1, 1989, pp. 31-39. [cited by applicant]
Mannino , et al., “Liposome Mediated Gene Transfer”, Bio Techniques, vol. 6, No. 7, Jul. 1, 1988, pp. 682-690. [cited by applicant]
Zeger , et al., “Longitudinal Data Analysis for Discrete and Continuous Outcomes”, Biometrics, vol. 42, No. 1, Macrh 1986, pp. 121-130. [cited by applicant]
Moorthy , et al., “Safety of DNA and Modified Vaccinia Virus Ankara Vaccines Against Liver Stage P.falciparum Malaria in Non-Immune Volunteers”, Vaccine, 21, 2003, pp. 1995-2002. [cited by applicant]
Mutabingwa , et al., “Maternal Malaria and Gravidity Interact to Modify Infant Susceptibility to Malaria”, PLoS, vol. 2, No. 12, Dec. 2005, pp. 1260-1268. [cited by applicant]
Nixon , et al., “Antibodies to Rhoptry-Associated Membrane Antigen Predict Resistance to Plasmodium falciparum”, The Journal of Infectious Diseases, vol. 192, Sep. 1, 2005, pp. 861-869. [cited by applicant]
Palacpac , et al., “Plasmodium Falciparum Serine Repeat Antigen 5 (SE36) as a Malaria Vaccine Candidate”, Vaccine, vol. 29, No. 35, DOI: 10.1016/J.VACCINE.2011.06.052, 2011, pp. 5837-5845. [cited by applicant]
Peterson , et al., “A Thermal Exhaust Port on the Death Star of Plasmodium Falciparum-Infected Erythrocytes”, Cell Press Reviews, Trends in Pharmacological Sciences, vol. 41, No. 8, 2020, pp. 508-511. [cited by applicant]
Pinkert , et al., “An Albumin Enhancer Located 10 kb Upstream Functions along with its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice”, Genes & Development, vol. 1, 1987, pp. 268-277. [cited by applicant]
Putrianti , et al., “The Plasmodium Serine-Type SERA Proteases Display Distinct Expression Patterns and Non-Essential in Vivo Roles During Life Cycle Progression of the Malaria Parasite”, Cell Microbiology, 12(6), Jun. … [cited by applicant]
Queen , et al., “Immunoglobulin Gene Transcription is Activated by Downstream Sequence Elements”, Cell, vol. 33, No. 3, Jul. 1983, pp. 741-748. [cited by applicant]
Raj , et al., “Antibodies to PfSEA-1 Block Parasite Egress from RBCs and Protect Against Malaria Infection”, Science, vol. 344, No. 6186, May 23, 2014, pp. 871-877. [cited by applicant]
Raj , et al., “Antibodies to Plasmodium Falciparum Glutamic Acid Rich Protein (PfGARP) Inhibit Parasite Growth by Arresting Trophozoite Development”, International Journal of Infectious Diseases, vol. 45, Apr. 1, 2016, … [cited by applicant]
Raj , et al., “Anti-PfGARP Activates Programmed Cell Death of Parasites and Reduces Severe Malaria”, Nature, vol. 582, Jun. 4, 2020, 28 pages. [cited by applicant]
Sabchareon , et al., “Parasitologic and Clinical Human Response to Immunoglobulin Administration in Falciparum Malaria”, Am. J. Trop. Med. Hyg., 45.3, 1991, pp. 297-308. [cited by applicant]
Sambrook , et al., “Molecular Cloning, A Laboratory Manual”, Cold Spring Harbor Laboratory Press, Ed. 2, 1989, pp. 348. [cited by applicant]
Schnieke , et al., “Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from Transfected Fetal Fibroblasts”, Science, vol. 278, No. 5346, Dec. 19, 1997, pp. 2130-2133. [cited by applicant]
Schultz , et al., “Expression and Secretion in Yeast of a 400-kdva Envelope Glycoprotein Derived from Epstein-Barr Virus”, Gene, vol. 54, No. 1, 1987, pp. 113-123. [cited by applicant]
Seed , et al., “An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its Receptor CD2”, Nature, vol. 329, No. 6142, Oct. 29, 1987, pp. 840-842. [cited by applicant]
Silmon , et al., “Global Identification of Multiple Substrates for Plasmodium Falciparum SUB1, an Essential Malarial Processing Protease”, Infect. Immun., 79(3), Mar. 2011, pp. 1086-1097. [cited by applicant]
Singh , et al., ““Correlation of T-Cell Response, Clinical Activity and Regulatory T-Cell Levels in Renal Cell Carcinoma Patients Treated with IMA901, A Novel Multi-Peptide Vaccine””, ASCO Journal, Abstract No. 3017, Ju… [cited by applicant]
Smith , et al., “Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector”, Molecular and Cellular Biology, Vo. 3, No. 12, Dec. 1983, pp. 2156-2165. [cited by applicant]
Smith , et al., “Single-Step Purification of Polypeptides Expressed in [cited by applicant]
Stover , et al., “New Use of BCG for Recombinant Vaccines”, Nature, vol. 51, Jun. 6, 1991, pp. 456-460. [cited by applicant]
Studier , et al., “Gene Expression Technology”, Methods in Enzymology, vol. 185, 1990, pp. 60-89. [cited by applicant]
Szoka , et al., “Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)”, Annual Review of Biophysics and Bioengineering, vol. 9, 1980, pp. 467-508. [cited by applicant]
Taylor, HM , et al., “The Malaria Parasite Cyclic GMP-Dependent Protein Kinase Plays A Central Role in Blood-Stage Schizogony”, Eukaryotic Cell, vol. 9, No. 1, DOI: 10.1128/EC.00186-09, Nov. 13, 2009, pp. 37-45. [cited by applicant]
Triglia , et al., “Structure of a Plasmodium falciparum Gene that Encodes a Glutamic Acid-Rich Protein (GARP)”, Molecular and Biochemical Parasitology, vol. 31, No. 2, 1988, pp. 199-201. [cited by applicant]
Trimble , et al., “A Phase I of Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3”, Clinical Cancer Research, vol. 15, 2009, pp. 361-367. [cited by applicant]
Wada , et al., “Codon Usage Tabulated from the GenBank Genetic”, Nucleic Acids Research, vol. 20, 1992, pp. 2111-2118. [cited by applicant]
Weintraub , et al., “Antisense RNA as a Molecular Tool for Genetic Analysis”, Reviews Trends in Genetics, vol. 1, No. 1, Dec. 1985, pp. 22-25. [cited by applicant]
Winoto , et al., “A Novel, Inducible T Cell-Specific Located at the 3′ End of the T Cell Receptor a Locus”, The EMBO Journal, vol. 8, No. 3, 1989, pp. 729-733. [cited by applicant]
Wolff , et al., “Direct Gene Transfer into Mouse Muscle in Vivo”, Science, vol. 247, No. 4949, Mar. 23, 1990, pp. 1465-1468. [cited by applicant]
Wrighton, K.H , “A Novel Vaccine Target for Malaria”, Nature Reviews I Microbiology, vol. 18, No. 361, 2020, 1 page. [cited by applicant]
Yeoh , et al., “Subcellular Discharge of a Serine Protease Mediates Release of Invasive Malaria Parasites from Host Erythrocytes”, Cell, vol. 131, No. 6 DOI: 10.1016/j.cell.2007.10.049, Dec. 1, 2007, pp. 1072-1083. [cited by applicant]